TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Favipiravir-HU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients between the ages of 18 and 65 years.~2. Patients with PCR confirmed SARS-CoV-2 infection~3. Asymptomatic or have mild only symptoms and symptoms are onset less than 5 days~4. Signed Informed Consent Form and Patient Information Leaflet~Exclusion Criteria:~1. Pregnant or possibly pregnant patients or lactating females~2. Patients have moderate to severe or immediately life-threatening COVID-19~3. Major risk factor onset (Obesity, Diabetes, COPD, Hypertension)~4. Patients with SpO2 less than 95% without oxygen therapy~5. Patients with severe hepatic impairment equivalent to Grade C on Child-Pugh classification~6. Patients with renal impairment requiring dialysis~7. Patients with disturbed consciousness such as disturbed orientation~8. Female patients who are woman of childbearing potential and unable to consent to use of dual contraception from the start of favipiravir administration to 30 days after the end of favipiravir administration. Dual contraception is a combination of two of the following: Barrier method of contraception: condoms (male or female) with orwithout a spermicidal agent, diaphragm or cervical cap with spermicide; IUD; Hormone-based contraceptive; Tubal ligation~9. Male patients whose are unable to consent to use of barrier method of contraception (condom) the start of favipiravir administration to 90 days after the end of favipiravir administration. Male patients who are planning to donate sperm in 90 days after the start of favipiravir administration.~10. Patients with hereditary xanthinuria~11. Patient with severe uncontrolled hyperuricaemia~12. Patients receiving immunosuppressants~13. Patients who received interferon-alpha or drugs with reported antiviral activity against SARS-CoV- 2 (hydroxychloroquine sulfate, chloroquine phosphate, lopinavir-ritonavir combination, ciclesonide, nafamostat mesylate, camostat mesylate, remdesivir, etc.) within 72 hours or Patients who receive forbidden concomitant medication~14. Any medical condition that the examining physician deems unsuitable for the patient to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Favipiravir HU + SOC (Type: EXPERIMENTAL): Favipiravir HU + SOC
- Placebo HU + SOC (Type: PLACEBO_COMPARATOR): Placebo HU + SOC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Utility of Wound Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* four compartment fasciotomies performed on one or both lower extremities~* subject and/or subject's legally authorized representative (next-of-kin) has voluntarily signed and dated informed consent.~Exclusion Criteria:~* inability to place wound VAC~* contraindications for wound VAC use~* pregnant females~* prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of advanced non small cell lung cancer, not amenable to surgical or curative radiation therapy (stage IIIB or IV);~* No prior or concomitant chemotherapy (adjuvant/neoadjuvant chemotherapy permitted if concluded at least one year prior to enrollment);~* ECOG performance status 2;~* Age: \> or = 18 and \< 70 years;~* Life expectancy at least 4 weeks;~* Normal bone marrow, hepatic and renal function defined as: neutrophils \> or = 2000/mm3, PLT \> or = 100,000/mm3, Hb \> or = 10.0 g/dl, Bilirubin \> or = 1.5 times the upper normal limit (UNL), AST and ALT \< or = 3 times the UNL (5 times in the presence of liver metastases), creatinine within normal limits;~* Signed informed consent.~Exclusion Criteria:~* Active systemic infections;~* Severe concomitant illness (congestive heart failure, angina pectoris, myocardial infarction within previous 6 months, cardiac arrhythmias under treatment, severe arterial hypertension, severe or uncontrolled diabetes mellitus);~* Inadequate hepatic or renal function;~* Radiation therapy ongoing or concluded within two weeks prior to enrollment;~* Symptomatic cerebral metastases;~* Previous chemotherapy for advanced disease;~* Any condition that would, in the investigator's opinion, limit the patients ability to provide informed consent or to comply with study procedures;~* Pregnant or nursing females;~* Any malignancy within the past 5 years (except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm B (Type: EXPERIMENTAL): combination chemotherapy
- Arm A (Type: ACTIVE_COMPARATOR): monochemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed pheochromocytoma and/or paraganglioma~Exclusion Criteria:~* pregnant woman~* breastfeeding woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BAT group (Type: EXPERIMENTAL): Patients will be divided in two groups for statistical analysis:~* patients with detectable BAT by PET-CT (BAT+)~* patients with no detectable BAT by PET-CT (BAT-)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Body Image Disorder in Anorexia Nervosa and Virtual Reality

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women, aged between 16 and 40~* Post-puberty~* Pure restrictive anorexia nervosa, diagnosis by the DSM-V~* BMI \<17.5~* Patient attending an outpatient clinic at the Bohars Psychiatric Hospital in France~* Having signed the Informed Consent Form~* For minor patients, signing the form of informed consent of both parents~Exclusion Criteria:~* Associated eating disorder (bulimia, or the binge eating / purging form of anorexia nervosa),~* Psychiatric disorders (characterized depressed, anxiety disorder)~* Neurological Disorders~* Mental retardation~* Abuse or addiction to alcohol~* Abuse or dependence on psychoactive substances in the previous year.~* Patient with a protective justice measure

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Virtual reality (Type: EXPERIMENTAL): The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Prior genetic confirmation of a known mitochondrial disease mutation~2. Neurological features of MELAS (can be based on medical history)~3. Elevated plasma lactate levels at Screening Visit (≥1.0 mmol/L)~4. Women of childbearing potential must have a negative pregnancy test prior to randomization and must agree to use protocol-specified contraception from the Screening Visit through 90 days after the final dose of study drug.~5. Male participants must be surgically sterile by vasectomy (conducted ≥60 days before the Screening Visit or confirmed via sperm analysis) or must agree to use protocol-specified contraception and agree to refrain from sperm donation from the Screening Visit through 90 days after the final dose of study drug.~6. Other inclusion criteria per protocol~Exclusion Criteria:~1. Positive pregnancy test at Screening or on Day 1~2. Hypotension defined as systolic blood pressure (BP) ≤90 mmHg or diastolic BP ≤60 mmHg at Screening or predose at Day 1~3. Hypertension defined as systolic BP \>160 mmHg or diastolic BP \>100 mmHg, at Screening or predose at Day 1~4. Uncontrolled diabetes~5. Severe gastrointestinal dysmotility as determined by the investigator that may impact compliance and/or oral drug administration, absorption and exposure.~6. Unable to fast for 3-4 hours after a meal~7. Unable or unwilling to adhere to the study schedule, lifestyle restrictions, assessment requirements or, in the clinical judgment of the investigator, is otherwise not suitable for study participation.~8. Current or past history of clinically significant cardiomyopathy and/or cardiac conduction abnormality~9. Used any nicotine-containing products (eg, cigarettes, e-cigarettes, vape pens, cigars) within 1 month of enrollment~10. Other exclusion criteria per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IW-6463 (Type: EXPERIMENTAL): Open-label IW-6463 15 mg once daily (QD), with possibility to dose reduce to 10 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Not currently participating in a drug or medical device clinical trial~* Male or female over the age of 18~* DSM - IV Diagnosis of major depression~* Positive family history of bipolar disorder or completed suicide~Exclusion Criteria:~* Not able to give informed consent~* Pregnant or breast-feeding~* Current additional psychiatric diagnoses including Panic Disorder, Post -Traumatic Stress Disorder (PTSD) or Psychosis~* History of mania or hypomania~* Active substance abuse or dependence in the last 6 months~* Current depressive episode less than 4 weeks or greater than 12 months in duration~* Current or prior adequate trial of lithium or paroxetine~* Current use of other medications such as antidepressants for the treatment of depression~* Clinically significant medical illness, in particular kidney problems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lithium group (Type: EXPERIMENTAL): Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
- paroxetine group (Type: ACTIVE_COMPARATOR): Start dose at 20 mg po od. If no clinical improvement(\<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Hysterectomized, menopausal women between the ages of 30 and 65 years of age (inclusive) with symptoms of estrogen and/or androgen deficiency not currently controlled by estrogen therapy as determined by patient report and the Investigator's clinical judgement

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have one of the following disease categories:~  * Acute myeloid leukemia (AML) beyond 2nd remission or relapsed/refractory disease~ * Acute lymphoblastic leukemia (ALL) beyond 2nd remission or relapsed/refractory disease~ * Chronic myeloid leukemia (CML) beyond 2nd chronic phase or in blast crises~ * Myelodysplastic syndrome (MDS)~ * Myeloproliferative disorders including myeloid metaplasia and myelofibrosis~ * High risk non-Hodgkin's lymphoma (NHL) in first remission~ * Relapsed or refractory NHL~ * Hodgkin's lymphoma (HL) beyond first remission~* Performance status by Karnofsky of \>= 70% or Lansky \> 70% for patients \< 16 years of age~* Human leukocyte antigen (HLA) mismatched related or unrelated donor identified 8/10 or 9/10~* Willingness to take oral medications during the transplantation period~* Willingness and ability to sign a written informed consent (assent if applicable)~Exclusion Criteria:~* Prior myeloablative allogeneic or autologous HSCT~* Human immunodeficiency virus (HIV) infection~* Pregnant or lactating females~* Evidence of uncontrolled active infection~* Down syndrome~* Serum creatinine (CR) \< 1.5mg/dl or 24 hour CR clearance \< 50 ml/min~* Direct bilirubin \> 2 x upper limit of normal (ULN)~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 x ULN~* Carbon monoxide diffusing capability test (DLCO) \> 60% predicted and in children- room air oxygen saturation \> 92%~* Left ventricular ejection fraction \< 45% and in children-shortening fraction \< 26%~* Fasting cholesterol \> 300 mg/dl or triglycerides \> 300 while on lipid lowering agents~* Patients who have received an investigational drug within 30 days of enrollment in study~* Patients with prior malignancies except basal cell carcinoma or treated carcinoma in-situ; cancer treated with curative intent \> 5 years will be allowed; cancer treatment with curative intent =\< 5 years will not be allowed

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (sirolimus, HSCT, MMF) (Type: EXPERIMENTAL): Patients receive sirolimus PO starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil IV or PO TID on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low Carb vs Normal Carb in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 - 40 years old~* BMI \> 30 and/or history of gestational diabetes mellitus~* Currently in first trimester of pregnancy with single fetus (e.g. not twins, triplets, etc.)~* Newborns of current participants~Exclusion Criteria:~* Diabetes (types 1 and 2)~* History of major chronic disease or blood clotting disorders (e.g., cancer, heart disease, kidney disease, hypertension)~* Known fetal anomaly~* History of eating disorders~* Current use of medications that affect appetite or insulin secretion/sensitivity (e.g. stimulants)~* Current use of illegal substances, antipsychotic or opioid substitution medications, alcohol, or tobacco

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 100 g carbs (Type: EXPERIMENTAL): 100 grams of carbohydrate allowance for the day
- MyPlate (Type: ACTIVE_COMPARATOR): Carbohydrate suggestions based on standard MyPlate. 45-65% kcal intake from carbs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Platelet Rich Plasma on Pain at Skin Graft Donor Sites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient requiring a split thickness skin graft and is above the age of 18.~Exclusion Criteria:~* Medical history of chronic pain at the donor site~* Inability to follow up~* Unable to participate in pre or post operative questionnaire inclusive of organic~* Traumatic, chemical or degenerative causes of altered mental sensorium~* Age \<18.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PRP (Type: EXPERIMENTAL): Intervention group will receive PRP instead of the standard of care for skin grafts. PRP Group-will remove surgical dressing post operative day 5. Donor site will be cleaned with soap and water daily and dressed with gauze daily until drainage stops.
- Control (Type: NO_INTERVENTION): Control group receiving the standard of care for skin grafts. Control Group-will remove gauze dressing post operative day 2 but leave adeptic. Donor site will be cleaned daily with soap and water. Gauze applied daily as needed for drainage and will be stopped when drainage stops. The adeptic, which forms a biologic dressing, will be removed by the patient over time as it lifts from the wound.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Improving Outcomes and Lowering Costs by Integration of Primary Care Providers and Pain Medicine Physicians for Pain Pts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1.Non-structural non-specific chronic low back pain of a least 3 months duration~2.18 years of age or older~3.Has a primary care provider (PCP)~Exclusion Criteria:~1. Unable to communicate with health care providers~2. Refuses to complete the required outcome measures~3. Unable to provide consent~4. Advanced medical illness (severe systemic disease)~5. Significant psychiatric history: a diagnosis of schizophrenia, bipolar disorder, or severe depression.~6. History of psychosis or psychiatric hospitalization, suicidal ideation or attempt.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (PMS Treatment) (Type: ACTIVE_COMPARATOR): Subjects will be treated monthly for 6 months by Pain Medicine Specialist (PMS) per standard protocol. The PCP will not be involved in the treatment.
- Group 2 (PCP Treatment) (Type: EXPERIMENTAL): Subjects will be treated monthly for 6 months by the Primary Care Provider (PCP).The PCP will be involved and a multimodal therapeutic strategy will be communicated to the PCP by the PMS. The PCP will make dosage based on an algorithm provided by the PMS on how to adjust drug doses over time. It is not intended that the PCP may have ongoing engagement with the PMS. A direct line of communication will be set up between the PCP and the data integration clinical coordinator to handle serious medical concerns.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ziprasidone and Sertraline in PTSD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Clinical diagnosis of Post-Traumatic Stress Disorder~Exclusion Criteria:~Lifetime psychotic disorders, current substance dependency, gravidity, lactation, tartrazine hypersensitivity, contraindication against sertraline or ziprasidone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility